Marc Rudoltz - 01 Nov 2021 Form 4 Insider Report for Tango Therapeutics, Inc. (TNGX)

Role
Chief Medical Officer
Signature
/s/ Douglas Barry, as attorney-in-fact
Issuer symbol
TNGX
Transactions as of
01 Nov 2021
Net transactions value
$0
Form type
4
Filing time
03 Nov 2021, 16:15:31 UTC
Previous filing
01 Nov 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TNGX Stock Option (Right to Buy) Award $0 +350,000 $0.000000 350,000 01 Nov 2021 Common Stock 350,000 $12.91 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option shall vest and become exercisable over a four-year period, at a rate of 25% on October 18, 2022, with the remaining option shares vesting in 36 equal monthly installments thereafter.